Loomis, Sayles & Company
STRO icon

Loomis, Sayles & Company’s Sutro Biopharma STRO Stock Holding History

Loomis, Sayles & Company’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-111,584
Closed -$16.6M – 1049
2021
Q4 		$16.6M Sell
111,584
-45,397
-29% -$8.13M 0.02% 332
2021
Q3 		$29.7M Buy
156,981
+24,180
+18% +$4.6M 0.04% 252
2021
Q2 		$24.7M Sell
132,801
-2,698
-2% -$528K 0.03% 273
2021
Q1 		$30.8M Buy
+135,499
New +$32.2M 0.04% 225

Other funds holding STRO

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Loomis, Sayles & Company's STRO Position: Q1 2022 in Review

Loomis, Sayles & Company sold out of Sutro Biopharma (STRO) in Q1 2022, closing a stake of 111,584 shares — an estimated $16.6M sold.

Loomis, Sayles & Company first reported a position in STRO in Q1 2021 and held it in 4 quarters. The position peaked at $30.8M in Q1 2021. 114 funds tracked by Wall St. Rank hold STRO as of Q1 2022.

  • Loomis, Sayles & Company reported no remaining Sutro Biopharma position as of Q1 2022 after selling out during the quarter.
  • Loomis, Sayles & Company sold 111,584 Sutro Biopharma shares in Q1 2022, an estimated $16.6M.
  • Loomis, Sayles & Company first reported a position in Sutro Biopharma in Q1 2021 and held it in 4 quarters.
  • Loomis, Sayles & Company's Sutro Biopharma position peaked at $30.8M in Q1 2021.
  • 114 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2022.

Based on Loomis, Sayles & Company's 13F filing for Q1 2022, filed 13 May 2022.